Portola Pharma (PTLA) Tops Q3 EPS by 19c

Portola Pharma (NASDAQ: PTLA) reported Q3 EPS of ($1.05), $0.19 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $2.45 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Rothschild Redburn Upgrades Apple (AAPL) to Buy
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform